Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 8/20 | 0.45 |
| ▸ | CA2 known ✓ | P00918 | 8/20 | 0.45 |
| ▸ | CA4 known ✓ | P22748 | 8/20 | 0.45 |
| ▸ | CA9 | Q16790 | 8/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL83681 | 0.85 | CA1 (0.44) | CA1CA2CA4CA9TAAR1 | |
| SCHEMBL28531207 | 0.84 | CA1 (0.43) | CA1CA2CA4CA9TAAR1 | |
| Sulfuric Acid SCHEMBL28700686 | 0.82 | CA1 (0.46) | CA1CA2CA4CA9TAAR1 | |
| SCHEMBL2587081 | 0.80 | CA1 (0.43) | CA1CA2CA4CA9TAAR1 | |
| SCHEMBL366506 | 0.80 | CA1 (0.42) | CA1CA2CA4CA9TAAR1 | |
| Acetonitrile SCHEMBL28171050 | 0.79 | CA1 (0.40) | CA1CA2CA4CA9TAAR1 | |
| SCHEMBL657861 | 0.79 | CA1 (0.40) | CA1CA2CA4CA9TAAR1 | |
| SCHEMBL6019646 | 0.79 | CA1 (0.42) | CA1CA2CA4CA9TAAR1 | |
| SCHEMBL31397702 | 0.77 | TAAR1 (0.45) | CA1CA2CA4CA9TAAR1 | |
| SCHEMBL651045 | 0.77 | CA1 (0.39) | CA1CA2CA4CA9TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000695-A1 | SOLID AND ORAL ETOPOSIDE TONIRIBATE COMPOSITIONS | CELLACT PHARMA GMBH (DE) | 2026-01-01 | — | — | US | disclosed |
| EP-2190411-A2 | LIPOSOME COMPOSITIONS FOR IN VIVO ADMINISTRATION OF BORONIC ACID COMPOUNDS | Alza Corporation (US) | 2010-06-02 | — | — | EP | disclosed |
| EP-2190412-A2 | LIPOSOME FORMULATIONS OF BORONIC ACID COMPOUNDS | Alza Corporation (US) | 2010-06-02 | — | — | EP | disclosed |
| US-20090092661-A1 | LIPOSOME COMPOSITIONS FOR IN VIVO ADMINISTRATION OF BORONIC ACID COMPOUNDS | ALZA CORPORATION | 2009-04-09 | — | — | US | disclosed |
| US-20090092662-A1 | LIPOSOME FORMULATIONS OF BORONIC ACID COMPOUNDS | ALZA CORPORATION | 2009-04-09 | — | — | US | disclosed |
| WO-2009026427-A2 | LIPOSOME COMPOSITIONS FOR IN VIVO ADMINISTRATION OF BORONIC ACID COMPOUNDS | ALZA CORPORATION (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009026430-A2 | LIPOSOME FORMULATIONS OF BORONIC ACID COMPOUNDS | ALZA CORPORATION (US) | 2009-02-26 | — | — | WO | disclosed |
| EP-1807053-A1 | LIPOSOMAL FORMULATION OF BORTEZOMIB (PS-341) | ALZA CORPORATION (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1807052-A1 | LIPOSOME FORMULATION OF PEPTIDE BORONIC ACIDS COMPOUNDS | ALZA CORPORATION (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20060159736-A1 | Liposome formulations of boronic acid compounds | ALZA CORPORATION | 2006-07-20 | — | — | US | disclosed |
| US-20060153907-A1 | Liposome formulations of boronic acid compounds | ALZA CORPORATION | 2006-07-13 | — | — | US | disclosed |
| WO-2006052733-A1 | LIPOSOMAL FORMULATION OF BORTEZOMIB (PS-341) | ALZA CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006052734-A1 | LIPOSOME FORMULATION OF PEPTIDE BORONIC ACIDS COMPOUNDS | ALZA CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| EP-0949906-A4 | COMPOUND-LOADED LIPOSOMES AND METHODS FOR THEIR PREPARATION | HERMES BIOSCIENCES INC (US) | 2004-11-24 | — | — | EP | disclosed |
| US-6110491-A | THE CONCENTRATIONS OF BOTH THE COMPOUND AND THE POLYMER WITHIN THE LIPOSOMES ARE SEVERALFOLD HIGHER THAN THE COMPOUND AND POLYMER CONCENTRATION IN BULK-PHASE MEDIUM | HERMES BIOSCIENCES, INC. (US) | 2000-08-29 | — | — | US | disclosed |
| EP-0949906-A1 | COMPOUND-LOADED LIPOSOMES AND METHODS FOR THEIR PREPARATION | Hermes Biosciences Inc. (US) | 1999-10-20 | — | — | EP | disclosed |
| WO-1998017256-A1 | COMPOUND-LOADED LIPOSOMES AND METHODS FOR THEIR PREPARATION | KIRPOTIN DMITRI (US) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060153907-A1 | Liposome formulations of boronic acid compounds | XIAP, PSMB11, PSMB1 | CA1 804/4885CA2 2410/4885CA4 2335/4885 |
| US-20260000695-A1 | SOLID AND ORAL ETOPOSIDE TONIRIBATE COMPOSITIONS | TOP2B, TOP1, TOP2A | CA1 1335/4885CA2 1931/4885CA4 1481/4885 |
| US-20090092661-A1 | LIPOSOME COMPOSITIONS FOR IN VIVO ADMINISTRATION OF BORONIC ACID COMPOUNDS | LIPA, LPAR6, ABHD6 | CA1 502/4885CA2 874/4885CA4 1059/4885 |
| US-20090092662-A1 | LIPOSOME FORMULATIONS OF BORONIC ACID COMPOUNDS | PSMB1, PSMB11, PSMA6 | CA1 623/4885CA2 1694/4885CA4 1886/4885 |
| US-20060159736-A1 | Liposome formulations of boronic acid compounds | XIAP, BOLA2; BOLA2B, BCL6 | CA1 872/4885CA2 1973/4885CA4 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.